16 To 24 Amino Acid Residues In The Peptide Chain Patents (Class 514/21.4)
-
Patent number: 8742068Abstract: The present invention relates to the use of fragments of heat shock proteins for the treatment and/or prevention of autoimmune diseases such as arthritis or inflammatory diseases such as Inflammatory Bowel Diseases. Preferably bacterial and/or mammalian heat shock proteins belonging to the HSP70 families are used.Type: GrantFiled: July 7, 2008Date of Patent: June 3, 2014Assignee: Universiteit Utrecht Holding B.V.Inventors: Willem van Eden, Ruurd van der Zee
-
Patent number: 8741850Abstract: Compounds of general formula (1): X1Y1X2Y2X3Y3X4Y4Y5X5X6Y6X7Y7X8X9X10 wherein X1-X10 are any natural or unnatural amino acids and Y1 is Gln; Y2 is Met or Leu; Y3 is He; Y4 is Pro or Ser; Y5 is His or Gly; Y6 is Gln or Pro; Y7 is He or Tyr or their homolog or ortolog are described; these compounds are able to bind to the VEGF receptors and to modulate the angiogenesis mediated by the VEG.Type: GrantFiled: July 23, 2010Date of Patent: June 3, 2014Assignee: Advanced Accelerator Applications S.A.Inventors: Luca Domenico D'Andrea, Carlo Pedone, Maria Caterina Turco
-
Publication number: 20140147414Abstract: Pre-implantation factor (PIF) may be used to treat intracellular damage. Aspects of the invention are directed to a method of treating intracellular damage comprising administering PIF to a subject in need thereof. Some aspects may be directed to methods of increasing cytokine secretion in response to intracellular damage comprising administering PIF to a subject in need thereof. The intracellular damage may be a result of a disease such as Listeria monocytogenes infection, malaria, Lyme disease, cardiovascular disease, duodenal peptic ulcer, atherosclerosis, peritonitis or tuberculosis. In some aspects, a method of treating tuberculosis is disclosed, comprising administering PIF to a subject in need thereof. In some aspects, a method of treating atherosclerosis is disclosed, comprising administering PIF to a subject in need thereof. In some aspects, a method of treating peritonitis is disclosed, comprising administering PIF to a subject in need thereof.Type: ApplicationFiled: March 2, 2012Publication date: May 29, 2014Applicant: BIOINCEPT, LLCInventor: Eytan R. Barnea
-
Patent number: 8735360Abstract: Described herein are peptides, compositions, and related methods for treating upper gastrointestinal disorders and conditions (e.g., dyspepsia, gastroparesis, post-operative gastric ileus, a functional esophageal disorder, a functional gastroduodenal disorder, gastroesophageal reflux disease (GERD), or a duodenal or stomach ulcer) as well as other conditions and disorders that are described herein.Type: GrantFiled: December 7, 2010Date of Patent: May 27, 2014Assignee: Ironwood Pharmaceuticals, Inc.Inventors: Mark G. Currie, Daniel P. Zimmer, Angelika Fretzen, Marco Kessler, Brian Cali
-
Patent number: 8735353Abstract: The present invention provides polypeptides comprising or consisting of an amino acid sequence from thrombin, or a fragment, variant, fusion or derivative thereof, or a fusion of said fragment, variant or derivative thereof, for use in the treatment or prevention of inflammation and/or excessive coagulation of the blood. Related aspects of the invention provide isolated polypeptides comprising or consisting of an amino acid sequence of any one of SEQ ID NOs: 1 to 7, or a fragment, variant, fusion or derivative thereof, or a fusion of said fragment, variant or derivative thereof, which exhibit an anti-inflammatory activity, together with isolated nucleic acid molecules, vectors and host cells for making the same. Additionally provided are pharmaceutical compositions comprising a polypeptide of the invention, as well as methods of use of the same in the treatment and/or prevention of inflammation and/or excessive coagulation.Type: GrantFiled: September 22, 2010Date of Patent: May 27, 2014Assignee: XMedic ABInventors: Martina Kalle, Gopinath Kasetty, Nils Martin Malmsten, Praveen Papareddy, Artur Schmidtchen, Bjorn Ulrik Walse
-
Publication number: 20140140926Abstract: The present invention includes a method of modulating the phagocytic activity of at least one phagocyte in a subject. The present invention also includes a method of providing a composition resistant to phagocytosis to a subject. The present invention further includes a method of treating, ameliorating or preventing an inflammatory disease in a subject.Type: ApplicationFiled: February 7, 2012Publication date: May 22, 2014Applicant: The Trustees of the University of PennsylvaniaInventors: Dennis E. Discher, Pia L. Rodriguez Nunez, Diego A Pantano
-
Patent number: 8729030Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.Type: GrantFiled: November 12, 2010Date of Patent: May 20, 2014Assignee: Affymax, Inc.Inventors: Christopher P. Holmes, Qun Yin, Guy Lalonde, Peter J. Schatz, David Tumelty, Palani Balu, Genet Zemede
-
Patent number: 8729032Abstract: Provide are a peptide gel with practically sufficient mechanical strength and a self-assembling peptide capable of forming the peptide gel. The self-assembling peptide is formed of the following amino acid sequence: a1b1c1b2a2b3db4a3b5c2b6a4 where: a1 to a4 each represent a basic amino acid residue; b1 to b6 each represent an uncharged polar amino acid residue and/or a hydrophobic amino acid residue, provided that at least five thereof each represent a hydrophobic amino acid residue; c1 and c2 each represent an acidic amino acid residue; and d represents a hydrophobic amino acid residue.Type: GrantFiled: February 12, 2010Date of Patent: May 20, 2014Assignees: Menicon Co., Ltd., National University Corporation Okayama UniversityInventors: Yusuke Nagai, Hidenori Yokoi, Koji Uesugi, Keiji Naruse
-
Patent number: 8729031Abstract: Compounds of formula (IV) and pharmaceutical compositions comprising the same are described, wherein X1 and X2, R3, L, Ar1, p and Z have the values disclosed herein.Type: GrantFiled: February 2, 2010Date of Patent: May 20, 2014Assignee: Novacta Biosystems LimitedInventor: Sjoerd Nicolaas Wadman
-
Publication number: 20140135276Abstract: The invention provides a peptide or peptidomimetic that is derived from or based upon the amino acid sequence of the C-terminal ?-helix or hypervariable region (HVR) or a Ras protein, a nucleic acid encoding the peptide or peptidomimetic, and methods employing the same.Type: ApplicationFiled: May 25, 2012Publication date: May 15, 2014Applicants: CALIDRIS THERAPEUTICS, LTD., The Board of Trustees of the University of Illinois, The United States of America, as represented by the Secretary, Dep. of Health & Human Services, VANDERBILT UNIVERSITYInventors: Nadya I. Tarasova, Sergey G. Tarasov, Vadim Gaponenko, Joseph Kates, Alla Ivanova, Michael C. Dean
-
Publication number: 20140134237Abstract: The subject invention pertains to agonist peptides of type I interferons and methods of using the peptides. These peptides are based on the amino acid sequence of the C-terminus region of the type I IFN molecules and are capable of binding to the cytoplasmic domain of type I IFN receptors. Surprisingly, these peptides were found to possess the same or similar biological activity as that associated with the full-length, mature type I IFN proteins, even though these peptides do not bind to the extracellular domain of the type I IFN receptors. In one embodiment, the peptide is a peptide of IFN?. In another embodiment, the peptide is a peptide of IFN?. Exemplified peptides of the invention include those having SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:38, SEQ ID NO:39, and SEQ ID NO:40. The subject peptides have been shown to effect increased resistance to viral infection.Type: ApplicationFiled: December 11, 2013Publication date: May 15, 2014Inventors: HOWARD M. JOHNSON, CHULBUL M. AHMED
-
Publication number: 20140134188Abstract: The invention provides for a method for screening compounds that bind to and modulate the hair-specific G-protein coupled receptor, P2RY5. The invention farther provides for methods for controlling hair growth by administering a P2RY5 modulating compound to a subject.Type: ApplicationFiled: September 30, 2013Publication date: May 15, 2014Applicant: The Trustees of Columbia University in the City of New YorkInventor: Angela M. Christiano
-
Patent number: 8716244Abstract: The present invention relates to pharmaceutical compositions, food supplement compositions and cosmetic compositions comprising diaminooxidase, and to the use thereof.Type: GrantFiled: August 24, 2010Date of Patent: May 6, 2014Assignee: Sciotec Diagnostic Technologies GmbHInventors: Albert Missbichler, Franz Gabor, Herwig Reichl
-
Publication number: 20140121170Abstract: Novel peptides that inhibit the release of microparticles from cells are disclosed. The peptide contains at least one VGFPV motif at the N-terminal and has a length of 10-100 amino acids. Also disclosed is polynucleotide encoding the peptide, expression vectors carrying the polynucleotide, and methods for treating AIDS and tumors using the novel peptides.Type: ApplicationFiled: August 30, 2013Publication date: May 1, 2014Inventors: Vincent Craig BOND, Michael POWELL, MingBo HUANG, Syed ALI, Andrea D. RAYMOND, Martin Neville SHELTON, Francois Jean VILLINGER
-
Publication number: 20140121169Abstract: A method of treatment of inflamed, pre-cancerous or cancerous tissue or polyps in a mammalian subject is disclosed. The treatment involves administration of a composition of at least one peptide agonist of a guanylate cyclase receptor and/or other small molecules that enhance intracellular production of cGMP. The at least one peptide agonist of a guanylate cyclase receptor may be administered either alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The inhibitor may be a small molecule, peptide, protein or other compound that inhibits the degradation of cGMP. Without requiring a particular mechanism of action, this treatment may restore a healthy balance between proliferation and apoptosis in the subject's population of epithelial cells, and also suppress carcinogenesis.Type: ApplicationFiled: December 20, 2013Publication date: May 1, 2014Inventors: Kunwar Shailubhai, Gregory Nikiforovich, Gary S. Jacob
-
Publication number: 20140121167Abstract: Novel therapeutic compounds for use against Huntington's disease. More especially, an isolated peptide of size less than 100 amino acids and containing: a first sequence having at least 80% identity with sequence AASSG (SEQ ID NO: 1), or a second sequence having at least 80% identity with sequence XAGXDXXTEXPXS (SEQ ID NO: 2), where X designates any amino acid. The use of an isolated peptide of size less than 200 amino acids and containing the sequence(s) defined above, as a drug is also described.Type: ApplicationFiled: April 12, 2012Publication date: May 1, 2014Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE(CNRS), UNIVERSITE MONTPELLIER 2 SCIENCES ET TECHNIQUES, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)Inventors: Florence Maschat, Marie-Laure Parmentier, Nathalie Bonneaud, Yoan Arribat
-
Patent number: 8709995Abstract: The invention provides compositions and methods related to human telomerase reverse transcriptase (hTRT), the catalytic protein subunit of human telomerase. The polynucleotides and polypeptides of the invention are useful for diagnosis, prognosis and treatment of human diseases, for changing the proliferative capacity of cells and organisms, and for identification and screening of compounds and treatments useful for treatment of diseases such as cancers.Type: GrantFiled: August 20, 2007Date of Patent: April 29, 2014Assignees: Geron Corporation, The Regents of the University of ColoradoInventors: Thomas R. Cech, Joachim Lingner, Toru M. Nakamura, Karen B. Chapman, Gregg B. Morin, Calvin B. Harley, William H. Andrews
-
Patent number: 8710184Abstract: The present invention aims at providing motilin-like peptide compounds that maintain the gastrointestinal motility stimulating activity of native motilin and which are adapted to have higher absorbability upon transmucosal administration. Motilin derivatives were designed and synthesized in consideration of the pathway for the degradation of motilin at a site of its transmucosal absorption and the maintenance of motilin's physiological activity and compounds characterized by substitutions for the amino acid at position 21 of native motilin have been found to show higher absorbability upon transmucosal administration and yet maintain the same activity as motilin.Type: GrantFiled: July 29, 2010Date of Patent: April 29, 2014Assignee: Daiichi Sankyo Company, LimitedInventors: Seiji Sato, Takeshi Hanada, Naomi Wakabayashi, Yutaka Masuda, Yuriko Harada
-
Publication number: 20140113874Abstract: Compounds comprising peptides capable of binding C3 protein and inhibiting complement activation are disclosed. These cyclic compounds are modified to improve stability while maintaining substantially equivalent complement activation-inhibitory activity as compared with currently available compounds. The compounds comprise compstatin analogs in which the disulfide bond between C2 and C12 is modified via a thioether bond to form a cystathionine.Type: ApplicationFiled: September 21, 2011Publication date: April 24, 2014Applicant: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIAInventors: John D. Lambris, Wilfred A. Van Der Donk
-
Patent number: 8703702Abstract: The invention describes peptide analogues of ?-melanocyte-stimulating hormone (?-MSH), which possess an increased efficacy compared to the native ?-MSH peptide. The ?-MSH analogues exhibit increased anti-inflammatory effects and increased capability to prevent ischemic conditions compared to ?-MSH. The invention further discloses use of the peptides for the manufacture of pharmaceutical compositions for the treatment or prophylaxis of a condition in the tissue of one or more organs of a mammal, and moreover pharmaceutical compositions.Type: GrantFiled: June 3, 2013Date of Patent: April 22, 2014Assignee: AbbVie Inc.Inventors: Thomas E. N. Jonassen, Soren Nielsen, Jorgen Frokiaer, Bjarne Due Larsen
-
Patent number: 8703698Abstract: Peptides and mimetics of selected domains of mammalian serum amyloid A isoform 2.1 (SAA2.1) and compounds and compositions thereof are provided that enhance the effect on macrophage cholesterol ester hydrolase activity and/or inhibit acyl CoA:cholesterol acyl transferase activity. Methods of using these compositions in the treatment and/or prevention of atherosclerosis as well as coronary heart disease and cardiovascular disease are also provided.Type: GrantFiled: February 8, 2010Date of Patent: April 22, 2014Assignee: The University of ChicagoInventors: Robert Kisilevsky, Shui-Pang Tam, John B. Ancsin, Zongchao Jia
-
Patent number: 8697655Abstract: Provided is a peptide including the following amino acid sequence. Tyr-Xaa0-Xaa1-Tyr-Tyr-Xaa2-Xaa3-Tyr-Xaa4-Xaa5-Xaa6-Xaa7-Xaa8-Xaa9-Xaa10-Xaa11 (SEQ ID NO: 4: wherein Xaa0, Xaa1, Xaa2, Xaa3, Xaa4, Xaa5, Xaa6, Xaa7, Xaa8, Xaa9, Xaa10 and Xaa 11 represent any amino acid) or Tyr-Asn-Asp-Tyr-Tyr-Tyr-Tyr-Cys-Tyr-Arg-Asp-Tyr-Asp (SEQ ID NO: 20).Type: GrantFiled: September 10, 2012Date of Patent: April 15, 2014Assignee: RikenInventors: Akira Wada, Yoshihiro Ito, Takashi Kitajima
-
Patent number: 8697840Abstract: During lung injury, p53 expression increases, inducing plasminogen activator inhibitor-1 (PAI-1) while inhibiting expression of urokinase-type plasminogen activator (uPA) and its receptor (uPAR), resulting in apoptosis of lung epithelial cells (LECs). In the bleomycin lung injury model, p53 and PAI-1 are induced while uPA and uPAR are inhibited. A 20 residue peptide DGIWKASFTTFTVTKYWFYR termed PP-1 (the Cav-1 scaffolding domain) or peptide NYHYLESSMTALYTLGH, termed PP-2, protected LECs from bleomycin-induced apoptosis in vitro and in vivo and prevented subsequent pulmonary fibrosis by attenuating lung epitheilial damage. Pharmaceutical compositions, peptide multimers and deliverable polypeptides comprising the above peptides are dislcosed.Type: GrantFiled: March 5, 2009Date of Patent: April 15, 2014Assignee: Board of Regents, The University of Texas SystemInventors: Sreerama Shetty, Steven Idell
-
Patent number: 8691772Abstract: The present invention provides novel uses for peptide p277—positions 437-460 of human heat shock protein 60 (HSP60)—in modulation of immune responses and inflammatory diseases. The invention further provides novel uses for HSP60 and p277 in the treatment or prevention of hepatic disorders. The invention discloses methods for treating, preventing or ameliorating the symptoms of T cell mediated inflammatory and autoimmune disorders, including hepatic disorders, which comprise administering to a subject in need thereof a composition comprising as an active ingredient an effective quantity of a molecule selected from: HSP60, p277, fragments, analogs, homologs and derivatives thereof, and nucleic acids encoding same. Also disclosed are T cell vaccination methods for treating or preventing T cell mediated disorders.Type: GrantFiled: January 4, 2006Date of Patent: April 8, 2014Assignee: Yeda Research and Development Co. Ltd.Inventors: Irun R. Cohen, Alexandra Zanin-Zhorov, Guy Tal, Francisco Quintana, Meirav Pevsner, Osnat Lider, Lihi Lider
-
Patent number: 8691773Abstract: The invention relates to a peptide compound with biological activity, which in particular possesses antimicrobial properties, its preparation and its applications.Type: GrantFiled: October 6, 2008Date of Patent: April 8, 2014Assignee: Sanofi-Aventis SpAInventors: Philippe Bressollier, Maria Attilia Brugo, Pascale Robineau, Jean-Marie Schmitter, Maurice Sofeir, Maria Camino Urdaci, Bernard Verneuil
-
Patent number: 8691947Abstract: This invention is based in part on the elucidation of new structural conformations and functions of the sodium/potassium adenosine triphosphate synthase (Na/K ATPase), and especially elucidation of new binding sites and interactions. The present invention provides practical applications of several surprising structural and functional relationships between Na/K ATPase and compounds which interact with Na/K ATPase. Disclosure of these structures and relationships provides insight and practical solutions to chemically affecting not only the Na/K ATPase interactions, but also regulators known to be upstream and downstream.Type: GrantFiled: January 13, 2011Date of Patent: April 8, 2014Assignee: The University of ToledoInventors: Zi-Jian Xie, Qiqi Ye, Zhichuan Li
-
Publication number: 20140094409Abstract: Brain prorenin and the (pro)renin receptor (PRR) have a functional role in the development of hypertension. The present disclosure presents functional PRR antagonistic peptides (e.g., PR10, PR20, PR30, and PR40). In addition, modified peptides comprising one or more thioether-bridges that are stable and strong PRR antagonists are also provided. Methods for treating and preventing hypertension, including neurogenic hypertension, and diabetes with a PRR antagonist are also provided.Type: ApplicationFiled: September 19, 2013Publication date: April 3, 2014Inventor: Yumei FENG
-
Patent number: 8685925Abstract: The invention provides methods of treating stroke and related conditions exacerbated by fever and/or hyperglycemia by administering peptides or peptidomimetics that inhibit binding of NMDAR 2B to PSD-95 to a patient.Type: GrantFiled: July 10, 2007Date of Patent: April 1, 2014Assignee: Nono Inc.Inventor: Michael Tymianski
-
Publication number: 20140088025Abstract: Lyophilized pulmonary surfactants having an increased specific surface area and porosity are described. A method of making lyophilized pulmonary surfactants is described.Type: ApplicationFiled: November 27, 2013Publication date: March 27, 2014Applicant: DISCOVERY LABORATORIES, INC.Inventors: Sergio CESCO-CANCIAN, Thomas HOY, Edward H. TRAPPLER, Michael S. THOMAS
-
Publication number: 20140088023Abstract: The present invention provides materials and methods useful to treat various sGC?1-expressing cancers. Materials include peptides which interfere with sGC?1's pro-survival functions, thereby resulting in apoptosis of sGC?1-expressing cells. In addition, the present invention provides screening assays, diagnostic assays, methods to prognose, methods to treat, and kits.Type: ApplicationFiled: November 1, 2013Publication date: March 27, 2014Applicant: THE UNIVERSITY OF TOLEDOInventors: Lirim Shemshedini, Shao-Yong Chen, Changmeng Cai, Chen-Lin Hsieh
-
Publication number: 20140087993Abstract: Disclosed here is the rational design and use of potent and specific GPCR antagonist pepducins based on GPCR regions such as the third intracellular loop and adjacent regions.Type: ApplicationFiled: April 9, 2012Publication date: March 27, 2014Applicant: TUFTS MEDICAL CENTER, Inc.Inventors: Athan Kuliopulos, Lidija Covic
-
Publication number: 20140088026Abstract: Lyophilized pulmonary surfactants having an increased specific surface area and porosity are described. Methods of making the lyophilized pulmonary surfactants are also described.Type: ApplicationFiled: November 27, 2013Publication date: March 27, 2014Applicant: DISCOVERY LABORATORIES, INC.Inventors: Sergio CESCO-CANCIAN, Thomas HOY, Edward H. TRAPPLER, Michael S. THOMAS
-
Patent number: 8680046Abstract: Described herein are compositions and methods for inhibiting HIV integrase activity. Also described are methods of identifying agents that inhibit HIV integrase for use in treating or preventing HIV. Also disclosed are methods of identifying agents that inhibit HIV viral mutants that are resistant to integrase inhibitors.Type: GrantFiled: March 18, 2010Date of Patent: March 25, 2014Assignees: Integratech Proteomics, LLC, The United States of America, as represented by the Secretary of the Department of Health and Human ServicesInventors: Tanya Sandrock, Robert Craigie
-
Patent number: 8680058Abstract: The present invention relates to targeting peptides capable of specifically binding to microbial organisms (e.g., P. aeruginosa or S. mutans), antimicrobial peptides having antimicrobial activities, and specifically/selectively targeted antimicrobial peptides (STAMPs). In addition, the present invention provides methods of selectively killing or inhibiting microbial organisms by using the peptides or compositions provided by the present invention.Type: GrantFiled: November 2, 2010Date of Patent: March 25, 2014Assignees: The Regents of the University of California, C3 Jian, Inc.Inventors: Randal H. Eckert, Daniel K. Yarbrough, Wenyuan Shi, Maxwell H. Anderson, Fengxia Qi, Jian He, Ian H. McHardy
-
Patent number: 8674060Abstract: Loss of Wnt-5a protein expression in breast carcinoma patients is associated with a shorter recurrence-free survival as well as increased motility in mammary cell lines. Based on sequence analysis of Wnt-5a, peptide fragments were identified and investigated for their ability to mimic effects of the Wnt-5a protein on mammary cell adhesion and motility. Two of these peptides significantly increased adhesion and impaired the motility of non-tumorigenic breast cancer cell lines, both low in endogenous Wnt-5a protein expression. To identify the shortest possible peptide that still had an anti-motile effect, sequential deletions of two amino acids from the N-terminal side of the shorter of these two peptides were performed. The effect on tumor cell adhesion was gradually lost, and when only 6 amino acids remained the effect was not detectable. However, formulation of the N-terminal methionine of this hexapeptide restored its effect on adhesion and reduced tumor cell motility.Type: GrantFiled: November 28, 2007Date of Patent: March 18, 2014Assignee: Wntresearch ABInventor: Tommy Andersson
-
Patent number: 8673270Abstract: The invention provides RGD-containing cyclic peptidomimetics; conjugates of said peptidomimetics and a moiety of a payload selected from fluorescent probes, photosensitizers, chelating agents, or cytotoxic agents; and pharmaceutical compositions comprising these conjugates. The conjugates of the invention are useful both for diagnostic purposes and treatment of various diseases, disorders and conditions. More specifically, conjugates comprising fluorescent probes can be used for diagnostic purposes, e.g., visualization of organs and tissues, and diagnosis of tumors; conjugates comprising photosensitizers can be used for photodynamic therapy of both tumors and nonneoplastic tissues; conjugates comprising chelating agents can be used in radio imaging or radiotherapy; and conjugates comprising cytotoxic agents can be used for in targeted chemotherapy.Type: GrantFiled: October 22, 2009Date of Patent: March 18, 2014Assignee: Steba Biotech S.A.Inventors: Doron Eren, Tamar Yechezkel, Yoseph Salitra, Natalia Koudinova
-
Patent number: 8673860Abstract: The present invention relates to compositions comprising biologically active proteins linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of using such compositions in treatment of glucose-related diseases, metabolic diseases, coagulation disorders, and growth hormone-related disorders and conditions.Type: GrantFiled: February 3, 2010Date of Patent: March 18, 2014Assignee: Amunix Operating Inc.Inventors: Volker Schellenberger, Joshua Silverman, Chia-wel Wang, Benjamin Spink, Willem P. Stemmer, Nathan C. Geething, Wayne To, Jeffrey L. Cleland
-
Publication number: 20140073555Abstract: A method for treating disorders involving deregulation of cell proliferation and/or angiogenesis comprising the administration of an effective amount of a multivalent synthetic compound comprising a support on which at least 3 pseudopeptide units are grafted, said compound being of formula (I).Type: ApplicationFiled: June 26, 2013Publication date: March 13, 2014Applicant: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Jose Courty, Ara Hovanessian, Jean Paul Briand, Gilles Guichard, Yamina Hamma
-
Publication number: 20140066384Abstract: Described herein are polypeptides that home to developing microvasculature, (also referred to as developing microvessels), such as newly developing microvasculature in mammals, particularly in humans, and to DNA that encodes such polypeptides. These polypeptides are referred to herein as developing microvasculature homing polypeptides. In a specific embodiment, the homing peptides are collateral vessel endothelia (CVE) homing polypeptides, which have been shown to home to collateral vessel endothelia after ischemia.Type: ApplicationFiled: April 15, 2013Publication date: March 6, 2014Applicants: MedStar Health Research Institute, Inc., Georgetown UniversityInventors: Anton Wellstein, Marcel O. Schmidt, Stephan Zbinden, Mary Susan Burnett, Stephen E. Epstein
-
Publication number: 20140066388Abstract: Disclosed are compositions and methods for treating or preventing diseases or disorders associated with mitochondrial CaMKII activity.Type: ApplicationFiled: September 4, 2013Publication date: March 6, 2014Applicant: UNIVERSITY OF IOWA RESEARCH FOUNDATIONInventors: Mark E. Anderson, Mei-ling A. Joiner, Aliasger K. Salem, Amaraporn Wongrakpanich, Frederick E. Domann, Duane D. Hall, Olha M. Koval, Douglas R. Spitz
-
Publication number: 20140065175Abstract: The invention relates to the technological sector of the transport and delivery of molecules into cells, either at cytoplasm or at nucleus or inter-cells (cell to cell transport), using peptides binding proteins from the cell microtubule motor complex, preferably dynein-binding peptides, as carrier/delivery peptides; or functionalized structures, as nanoparticles, linked to said carrier/delivery peptides. This delivery can be useful in many technical fields comprising, among some others: diagnosis, therapy and pharmacology.Type: ApplicationFiled: February 17, 2012Publication date: March 6, 2014Inventors: M. Covadonga Alonso Martí, José Ángel Martínez Escribano
-
Publication number: 20140066387Abstract: The present invention concerns the field of functionalized self-assembling peptides suitable for obtaining hydrogels for use in a wide range of applications in the biomedical field, such as for the development of biomaterials for regenerative medicine and basic science research.Type: ApplicationFiled: March 14, 2012Publication date: March 6, 2014Applicant: NANOMED3D S.R.L.Inventors: Fabrizio Gelain, Angelo Luigi Vescovi
-
Patent number: 8663617Abstract: The current invention relates to methods and compositions for the treatment of wounds in a mammalian subject. Particularly, the invention relates to novel polypeptides and encoding nucleic acids that stimulate keratinocyte and endothelial cell motility and/or proliferation.Type: GrantFiled: October 16, 2012Date of Patent: March 4, 2014Assignee: Tufts UniversityInventor: Ira M Herman
-
Publication number: 20140051647Abstract: This invention provides a TNFR2 expression-inducing composition including as an active ingredient a peptide having TNFR2 expression-inducing activity, and a method for producing cells that express TNFR2 selectively by use of the composition. The cell production method provided by this invention includes: culturing at least one species of cells capable of expressing TNF receptor 2, and supplying the cells with a synthetic peptide consisting of a nuclear localization signal sequence (NLS) or a nucleolar localization signal sequence (NoLS) to enhance TNFR2 expression in the cells.Type: ApplicationFiled: April 17, 2012Publication date: February 20, 2014Applicant: TOAGOSEI CO. LTD.Inventors: Nahoko Kobayashi, Tetsuhiko Yoshida, Mikio Niwa
-
Publication number: 20140051646Abstract: The present invention discloses cell penetrating peptides and conjugates of a cell penetrating peptide and a cargo molecule.Type: ApplicationFiled: August 14, 2013Publication date: February 20, 2014Applicant: Medical Research CouncilInventors: Michael John Gait, Andrey Alexandrovich Arzumanov, Gabriela Dimitroval Ivanova
-
Patent number: 8653038Abstract: An HLA-A*1101-restricted WT1 peptide, specifically, a peptide comprising an amino acid sequence consisting of 9 contiguous amino acids from a WT1 protein, wherein the peptide has an ability to bind to an HLA-A*1101 molecule, and has an ability to induce a CTL is described. A peptide dimer having an ability to bind to an HLA-A*1101 molecule and having an ability to induce a CTL, in which two peptide monomers each comprising an amino acid sequence cons sting of 9 contiguous amino acids from a WT1 protein and comprising at least one cysteine residue are bound to each other through a disulfide bond is also described. Furthermore, a polynucleotide encoding the peptide, a pharmaceutical composition for the treatment and/or prevention of a cancer comprising the same and the like are provided.Type: GrantFiled: December 14, 2007Date of Patent: February 18, 2014Assignee: International Institute of Cancer Immunology, Inc.Inventor: Haruo Sugiyama
-
Patent number: 8653039Abstract: Peptides derived from cancer specific isoform of proliferating cell nuclear antigen (caPCNA, also known as csPCNA) or from nmPCNA-interacting proteins interfere with intracellular protein-protein interaction, thereby causing a reduction in the proliferative potential of cancer. These peptides serve as therapeutic compositions to reduce the proliferation of cancer cells and also augment existing chemotherapeutic methods.Type: GrantFiled: February 16, 2007Date of Patent: February 18, 2014Inventors: Robert J. Hickey, Linda H. Malkas
-
Publication number: 20140045769Abstract: The present invention relates to peptides having one or more stable, internally-constrained HBS ?-helices, where the peptide is capable of interacting with Ras and related proteins.Type: ApplicationFiled: March 2, 2012Publication date: February 13, 2014Applicant: NEW YORK UNIVERSITYInventors: Paramjit Arora, Dafna Bar-Sagi, Anupam Patgiri, Kamlesh Yadav
-
Publication number: 20140045759Abstract: Compositions that include isolated peptides that inhibit TLR-4 signaling pathways and inflammation are disclosed. Methods of producing and using the compositions to inhibit TLR-4 signaling and/or inflammation are also disclosed herein.Type: ApplicationFiled: August 30, 2013Publication date: February 13, 2014Applicant: The Board of Regents of the University of OklahomaInventor: Shanjana Awasthi
-
Patent number: 8648043Abstract: A method of inhibiting the binding between N-methyl-D-aspartate receptors and neuronal proteins in a neuron the method comprising administering to the neuron an effective inhibiting amount of a peptide replacement agent for the NMDA receptor or neuronal protein interaction domain that effect said inhibition of the NMDA receptor neuronal protein. The method is of value in reducing the damaging effect of injury to mammalian cells. Postsynaptic density-95 protein (PSD-95) couples neuronal N-methyl-D-aspartate receptors (NMDARs) to pathways mediating excitotoxicity and ischemic brain damage. This coupling was disrupted by transducing neurons with peptides that bind to modular domains on either side of the PSD-95/NMDAR interaction complex. This treatment attenuated downstream NMDAR signaling without blocking NMDAR activity, protected cultured cortical neurons from excitotoxic insults and dramatically reduced cerebral infarction volume in rats subjected to transient focal cerebral ischemia.Type: GrantFiled: September 11, 2009Date of Patent: February 11, 2014Assignee: NONO Inc.Inventor: Michael Tymianski